Maravai LifeSciences (NASDAQ:MRVI – Free Report) had its target price lifted by Wells Fargo & Company from $5.50 to $6.50 in a research note released on Friday,Benzinga reports. The brokerage currently has an overweight rating on the stock.
Other equities analysts have also issued reports about the company. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $6.00 price target on shares of Maravai LifeSciences in a research report on Friday, May 8th. UBS Group reiterated a “reduce” rating on shares of Maravai LifeSciences in a research note on Wednesday, June 3rd. Weiss Ratings raised shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 29th. Finally, Wall Street Zen downgraded shares of Maravai LifeSciences from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Three investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $5.83.
Read Our Latest Research Report on MRVI
Maravai LifeSciences Trading Down 0.3%
Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.02. Maravai LifeSciences had a negative return on equity of 15.34% and a negative net margin of 37.07%.The company had revenue of $51.44 million for the quarter, compared to analysts’ expectations of $48.67 million. Research analysts predict that Maravai LifeSciences will post -0.2 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total transaction of $126,500.00. Following the completion of the sale, the general counsel owned 360,767 shares in the company, valued at $1,825,481.02. This trade represents a 6.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.49% of the company’s stock.
Institutional Trading of Maravai LifeSciences
A number of hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada raised its holdings in Maravai LifeSciences by 49.0% in the first quarter. Royal Bank of Canada now owns 9,761 shares of the company’s stock valued at $27,000 after acquiring an additional 3,209 shares in the last quarter. Quantessence Capital LLC bought a new position in shares of Maravai LifeSciences during the third quarter worth about $31,000. Abel Hall LLC acquired a new position in Maravai LifeSciences in the third quarter worth about $33,000. CIBC Bancorp USA Inc. bought a new stake in Maravai LifeSciences in the third quarter valued at about $33,000. Finally, Virtu Financial LLC acquired a new stake in Maravai LifeSciences during the fourth quarter valued at approximately $34,000. Institutional investors and hedge funds own 50.25% of the company’s stock.
Key Stories Impacting Maravai LifeSciences
Here are the key news stories impacting Maravai LifeSciences this week:
- Positive Sentiment: Maravai reported second-quarter revenue of $51.44 million, exceeding analysts’ $48.67 million consensus estimate. The company also reported a quarterly loss per share of approximately $0.02, narrower than expectations of roughly $0.04-$0.05, according to the earnings coverage. Maravai LifeSciences Reports Second Quarter 2026 Financial Results
- Positive Sentiment: Wells Fargo’s higher valuation target and “Overweight” rating indicate greater confidence in Maravai’s growth outlook and provide a near-term catalyst for the shares. Wells Fargo price target report
- Neutral Sentiment: Management issued fiscal 2026 revenue guidance of $205 million to $215 million, a range that broadly brackets the $210.4 million analyst consensus. The update offers limited surprise but provides visibility into the company’s expected performance. Maravai LifeSciences 2026 Q2 Results Presentation
- Negative Sentiment: Maravai remains unprofitable, with a negative net margin and negative return on equity. Continued quarterly losses could limit the stock’s upside unless revenue growth translates into improving profitability. Maravai LifeSciences Q2 earnings coverage
Maravai LifeSciences Company Profile
Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.
Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.
Read More
- Five stocks we like better than Maravai LifeSciences
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
